Due to their programmable design in molecular level and excellent selectivity in targeted recognition and transportation, AptNAs displayed a highly-specific toxicity against cancer cells and a significantly down-regulated expression of drug efflux pump protein P-gp, which synergistically enhanced the anti-cancer effect. The gene discussed is PGP; the disease is cancer.